Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess

Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound

(2010) Toru Miyoshi et al.   ATHEROSCLEROSIS

Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4

(2010) Jun Song et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults

(2008) E J Rhee et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Polycystic ovary syndrome in adolescents

(2008) S Franks   INTERNATIONAL JOURNAL OF OBESITY

Metformin Treatment for Four Years to Reduce Total and Visceral Fat in Low Birth Weight Girls with Precocious Pubarche

(2008) Lourdes Ibáñez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes

(2008) Anna Cabré et al.   JOURNAL OF LIPID RESEARCH

Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets

(2008) Masato Furuhashi et al.   NATURE REVIEWS DRUG DISCOVERY

Clinical spectrum of premature pubarche: Links to metabolic syndrome and ovarian hyperandrogenism

(2008) Lourdes Ibáñez et al.   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients

(2007) Blai Coll et al.   ATHEROSCLEROSIS